Scientists investigate why immunotherapy attacks the nervous system

NCT ID NCT07456358

Recruiting now Knowledge-focused Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 08, 2026 · Updated 2 times

Summary

This study looks at why some cancer patients develop neurological problems after receiving immunotherapy drugs called checkpoint inhibitors. Researchers will analyze spinal fluid and blood from 160 participants to find immune cells that may mistakenly attack the nervous system. The goal is to better understand the causes of these side effects, not to test a new treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this research could help doctors predict or prevent nerve-related side effects in cancer patients receiving immunotherapy.
What could go wrong: This is an observational study, not a treatment trial. It is still in early stages and may not lead to direct clinical changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTO IMMUNE DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune disease autoimmune disorder of central nervous system nervous system disorder normal pressure hydrocephalus pseudotumor cerebri

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AUTO IMMUNE DISEASE NEUROLOGICAL DISEASES

Contacts and locations

Locations

Fondation Rotschild
NOT_YET_RECRUITING

Paris, France
Hôpital Bicêtre AP-HP
RECRUITING

Le Kremlin-Bicêtre, France
Hôpital Saint Louis
RECRUITING

Paris, France
Hôpital Saint Louis AP-HP
RECRUITING

Paris, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.